Key facts
- This page summarizes Hugh M. Evans's Form 3 filing for CollPlant Biotechnologies Ltd (CLGN).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 27 Apr 2026, 15:40.
Hugh M. Evans - 18 Mar 2026 Form 3 Insider Report for CollPlant Biotechnologies Ltd (CLGN)
- Reporting relationship
- Director
- Issuer ticker
- CLGN
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Hugh M Evans
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Hugh M. Evans filed Form 3 for CollPlant Biotechnologies Ltd (CLGN) on 27 Apr 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001686408
Primary reporting owner
Evans Hugh M
- Relationship
- Director
- Address
- C/O COLLPLANT BIOTECHNOLOGIES LTD., 4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK, REHOVOT, ISRAEL
- Signature
- /s/ Hugh M Evans
- Signature date
- 27 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLGN
holding
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,000
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
CLGN
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 315,554
- Date
- 18 Mar 2026
- Ownership
- Direct
CLGN
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 10,000
- Date
- 18 Mar 2026
- Ownership
- See Footnote
- Footnotes
- F2
CLGN
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 15,000
- Date
- 18 Mar 2026
- Ownership
- See Footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLGN
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 23,000
- Exercise price
- $6.39
- Footnotes
- F4
CLGN
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 24,000
- Exercise price
- $6.39
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Of the restricted share units reported herein, 3,125 units are vested, and the remaining 6,875 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
Footnote F2
Ordinary shares beneficially owned by Reporting Person's spouse.
Footnote F3
Shares held by an irrevocable trust for the benefit of the reporting person's children of which the reporting person is a trustee. The reporting person disclaims any beneficial ownership in these shares.
Footnote F4
These options are fully vested and exercisable.
Footnote F5
22,500 options are fully vested and exercisable. The remaining options shall vest and become exercisable on May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.